This protocol is judged by an institutional overview board, an impartial team that critiques any clinical trials involving humans. If a review includes a Program I drug, once the board approves the protocol as ethical, the researchers need to submit an application for an investigational new drug (IND) number from the FDA.With the doses packaged an